1nessAgency

1nessAgency Insights

Healthcare digital marketing insights narrated by AI. Compliance strategy, patient acquisition, and AI optimization from 1nessAgency.

Vizitează neapărat site-ul podcastului și susține-i creatorul: www.1nessagency.com

Autor

1nessAgency

Categorie

Business

Site-ul podcastului

www.1nessagency.com

Cel mai nou episod

19 nov. 2026

Unde asculți?

Podcasturi în aplicație Replaio Radio În curând

Podcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor

Descarcă din Google Play Instalează gratuit Android 10 mil.+ descărcări · nota 4,7+ iOS în curând

Episoade

Workers' Health Files Become Regulatory Target as Critics Warn Dangers Ahead 08.05.2026

The Office of Personnel Management is pursuing unredacted health records from insurers covering millions of federal workers , and the fallout reaches far beyond Washington. Reported by KFF Health News in April and May 2026, the OPM data request represents the most aggressive federal incursion into e

Workers' Health Files Become Regulatory Target as Critics Warn Dangers Ahead 08.05.2026

The Office of Personnel Management is pursuing unredacted health records from insurers covering millions of federal workers , and the fallout reaches far beyond Washington. Reported by KFF Health News in April and May 2026, the OPM data request represents the most aggressive federal incursion into e

Aetna's Insurance Gains Push CVS to Lift Annual Outlook 07.05.2026

CVS did not release granular Q1 2026 segment data at the time this article was prepared, but the company publicly raised its full-year guidance, a move that typically reflects management confidence in sustained margin improvement across its insurance, pharmacy, and care delivery businesses [1]. Aetn

White House Order Pushes FDA to Fast-Track Serious Mental Health Treatments 07.05.2026

The FDA's announcement names specific companies, specific compounds, and specific conditions. Three firms received national priority vouchers for psilocybin studies targeting treatment-resistant depression and major depressive disorder, and for methylone targeting PTSD [1]. DemeRx NB received cleara

Aetna's Insurance Gains Push CVS to Lift Annual Outlook 07.05.2026

CVS did not release granular Q1 2026 segment data at the time this article was prepared, but the company publicly raised its full-year guidance, a move that typically reflects management confidence in sustained margin improvement across its insurance, pharmacy, and care delivery businesses [1]. Aetn

White House Order Pushes FDA to Fast-Track Serious Mental Health Treatments 07.05.2026

The FDA's announcement names specific companies, specific compounds, and specific conditions. Three firms received national priority vouchers for psilocybin studies targeting treatment-resistant depression and major depressive disorder, and for methylone targeting PTSD [1]. DemeRx NB received cleara

FDA Clears First Gene Therapy For Rare Blood Disorder, Opening Door to New Treatment Class 27.04.2026

The FDA's March 26, 2026 approval of Kresladi (marnetegragene autotemcel) for severe Leukocyte Adhesion Deficiency Type I marks a turning point not just for pediatric immunology, but for how rare disease marketers must operate. Rocket Pharmaceuticals now holds the first-ever FDA-approved gene therap

Affordable Care Act Subsidy Lapse Erases 100,000 Patient Visits at Nation's Largest For-Profit Health System 27.04.2026

HCA Healthcare reported a $150 million revenue hit in Q1 2026 directly attributed to the lapse in Affordable Care Act subsidies, a figure that translates to roughly 100,000 patient visits at typical reimbursement rates. The nation's largest for-profit health system just quantified what most marketing

FDA Clears First Gene Therapy For Rare Blood Disorder, Opening Door to New Treatment Class 27.04.2026

The FDA's March 26, 2026 approval of Kresladi (marnetegragene autotemcel) for severe Leukocyte Adhesion Deficiency Type I marks a turning point not just for pediatric immunology, but for how rare disease marketers must operate. Rocket Pharmaceuticals now holds the first-ever FDA-approved gene therap

Affordable Care Act Subsidy Lapse Erases 100,000 Patient Visits at Nation's Largest For-Profit Health System 27.04.2026

HCA Healthcare reported a $150 million revenue hit in Q1 2026 directly attributed to the lapse in Affordable Care Act subsidies—a figure that translates to roughly 100,000 patient visits at typical reimbursement rates. The nation's largest for-profit health system just quantified what most marketing

FDA Unlocks Gene Therapy For Hearing Loss, Signaling Shift in Rare Disease Treatment 24.04.2026

The FDA just approved a gene therapy for genetic hearing loss in 61 days, tied for the fastest biologics license application approval in modern agency history. For healthcare marketers in the rare disease and precision medicine space, this velocity changes patient identification timelines, reimbursem

FDA Approves Psychedelic Drug Trials, Signaling Shift in Mental Health Treatment 24.04.2026

The FDA's decision in early 2026 to back three psychedelic drug studies for mental illness treatment marks the clearest regulatory signal yet that psychedelic-assisted therapy is on a trajectory toward mainstream clinical use , and healthcare systems that wait for full approval before building their

FDA Unlocks Gene Therapy For Hearing Loss, Signaling Shift in Rare Disease Treatment 24.04.2026

The FDA just approved a gene therapy for genetic hearing loss in 61 days—tied for the fastest biologics license application approval in modern agency history. For healthcare marketers in the rare disease and precision medicine space, this velocity changes patient identification timelines, reimbursem

FDA Approves Psychedelic Drug Trials, Signaling Shift in Mental Health Treatment 24.04.2026

The FDA's decision in early 2026 to back three psychedelic drug studies for mental illness treatment marks the clearest regulatory signal yet that psychedelic-assisted therapy is on a trajectory toward mainstream clinical use , and healthcare systems that wait for full approval before building their

UnitedHealth Hikes Profit Outlook After Better-Than-Expected First Quarter 22.04.2026

UnitedHealth Group raised its 2026 profit outlook following first-quarter earnings that exceeded Wall Street expectations, extending the nation's largest health insurer's financial outperformance at a moment when providers face margin pressure from real estate costs, regulatory compliance, and reimb

New CMS Rule Requires States to Audit Every Medicaid Provider in Sweeping Compliance Push 22.04.2026

CMS announced in 2026 its intent to require states to conduct audits of Medicaid-enrolled providers, according to reporting from Becker's Hospital Review [1]. While the regulatory machinery is still being assembled , state implementation timelines, audit scope, and enforcement thresholds remain subj

Biotech and Pharma Brace For Continued N.I.H. Funding Cuts in Second Trump Term 22.04.2026

The slowdown in National Institutes of Health grant awards accelerating into 2026 is doing more than shrinking research budgets , it is restructuring the competitive landscape for academic medical centers, community hospitals, and specialty practices that built patient acquisition strategies around

What Healthcare Marketers Need to Know About Ibogaine's Clinical Promise and Regulatory Path 22.04.2026

The most consequential psychedelic therapy conversation of 2026 is not about psilocybin or ketamine , it is about ibogaine, a Schedule I substance derived from the African iboga plant that is attracting serious federal attention for its potential to treat opioid use disorder (OUD). As the FDA naviga

UnitedHealth Hikes Profit Outlook After Better-Than-Expected First Quarter 22.04.2026

UnitedHealth Group raised its 2026 profit outlook following first-quarter earnings that exceeded Wall Street expectations, extending the nation's largest health insurer's financial outperformance at a moment when providers face margin pressure from real estate costs, regulatory compliance, and reimb

New CMS Rule Requires States to Audit Every Medicaid Provider in Sweeping Compliance Push 22.04.2026

CMS announced in 2026 its intent to require states to conduct audits of Medicaid-enrolled providers, according to reporting from Becker's Hospital Review [1]. While the regulatory machinery is still being assembled , state implementation timelines, audit scope, and enforcement thresholds remain subj

Biotech and Pharma Brace For Continued N.I.H. Funding Cuts in Second Trump Term 22.04.2026

The slowdown in National Institutes of Health grant awards accelerating into 2026 is doing more than shrinking research budgets , it is restructuring the competitive landscape for academic medical centers, community hospitals, and specialty practices that built patient acquisition strategies around

What Healthcare Marketers Need to Know About Ibogaine's Clinical Promise and Regulatory Path 22.04.2026

The most consequential psychedelic therapy conversation of 2026 is not about psilocybin or ketamine , it is about ibogaine, a Schedule I substance derived from the African iboga plant that is attracting serious federal attention for its potential to treat opioid use disorder (OUD). As the FDA naviga

FDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordable 20.04.2026

The FDA's accelerated push to streamline biosimilar development and expand state drug importation programs in 2026 has opened a marketing opportunity most health systems haven't recognized: affordability messaging now belongs at the center of patient acquisition strategy, not buried in financial ass

Trump Signs Executive Order to Loosen Restrictions on Psychedelic Drugs 20.04.2026

A presidential executive order in April 2026 loosening restrictions on psychedelic drugs creates the first legitimate marketing opportunity for a substance class that has lived in regulatory limbo for half a century. Healthcare organizations and pharmaceutical companies now face a market with millio

FDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordable 20.04.2026

The FDA's accelerated push to streamline biosimilar development and expand state drug importation programs in 2026 has opened a marketing opportunity most health systems haven't recognized: affordability messaging now belongs at the center of patient acquisition strategy, not buried in financial ass

Ascultă podcastul 1nessAgency Insights în Replaio

Radio și podcasturi într-o singură aplicație - gratuit și fără înregistrare. Instaleaz-o azi și nu rata lansarea

Descarcă din Google Play

Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice